155 related articles for article (PubMed ID: 8319226)
41. Treatment for malignant pleural effusion of human lung adenocarcinoma by inhibition of vascular endothelial growth factor receptor tyrosine kinase phosphorylation.
Yano S; Herbst RS; Shinohara H; Knighton B; Bucana CD; Killion JJ; Wood J; Fidler IJ
Clin Cancer Res; 2000 Mar; 6(3):957-65. PubMed ID: 10741721
[TBL] [Abstract][Full Text] [Related]
42. Mesenchymal stem cells: potential precursors for tumor stroma and targeted-delivery vehicles for anticancer agents.
Studeny M; Marini FC; Dembinski JL; Zompetta C; Cabreira-Hansen M; Bekele BN; Champlin RE; Andreeff M
J Natl Cancer Inst; 2004 Nov; 96(21):1593-603. PubMed ID: 15523088
[TBL] [Abstract][Full Text] [Related]
43. Cyclooxygenase-2 expression influences the growth of human large and small cell lung carcinoma lines in athymic mice: impact of an organoselenium compound on growth regulation.
El-Bayoumy K; Rose DP; Papanikolaou N; Leszczynska J; Swamy MV; Rao CV
Int J Oncol; 2002 Mar; 20(3):557-61. PubMed ID: 11836568
[TBL] [Abstract][Full Text] [Related]
44. Human embryonal carcinoma grown in athymic mice and in vitro.
Tveit KM; Fodstad O; Brøgger A; Olsnes S
Cancer Res; 1980 Mar; 40(3):949-53. PubMed ID: 7471109
[TBL] [Abstract][Full Text] [Related]
45. Phosphocyclocreatine is the dominant form of cyclocreatine in control and creatine transporter deficiency patient fibroblasts.
Gorshkov K; Wang AQ; Sun W; Fisher E; Frigeni M; Singleton M; Thorne N; Class B; Huang W; Longo N; Do MT; Ottinger EA; Xu X; Zheng W
Pharmacol Res Perspect; 2019 Dec; 7(6):e00525. PubMed ID: 31859463
[TBL] [Abstract][Full Text] [Related]
46. Tyrosine Phosphorylation of Mitochondrial Creatine Kinase 1 Enhances a Druggable Tumor Energy Shuttle Pathway.
Kurmi K; Hitosugi S; Yu J; Boakye-Agyeman F; Wiese EK; Larson TR; Dai Q; Machida YJ; Lou Z; Wang L; Boughey JC; Kaufmann SH; Goetz MP; Karnitz LM; Hitosugi T
Cell Metab; 2018 Dec; 28(6):833-847.e8. PubMed ID: 30174304
[TBL] [Abstract][Full Text] [Related]
47. Cyclocreatine (1-carboxymethyl-2-iminoimidazolidine) inhibits the replication of human herpes viruses.
Lillie JW; Smee DF; Huffman JH; Hansen LJ; Sidwell RW; Kaddurah-Daouk R
Antiviral Res; 1994 Apr; 23(3-4):203-18. PubMed ID: 8042860
[TBL] [Abstract][Full Text] [Related]
48. Inhibition of neoplastic growth by N-homocysteine thiolactonyl retinamido cobalamin.
McCully KS; Tzanakakis GN; Vezeridis MP
Res Commun Chem Pathol Pharmacol; 1989 Oct; 66(1):117-22. PubMed ID: 2616893
[TBL] [Abstract][Full Text] [Related]
49. Enhanced ability of skeletal muscle containing cyclocreatine phosphate to sustain ATP levels during ischemia following beta-adrenergic stimulation.
Turner DM; Walker JB
J Biol Chem; 1987 May; 262(14):6605-9. PubMed ID: 3571272
[TBL] [Abstract][Full Text] [Related]
50. Cyclocreatine accumulation leads to cellular swelling in C6 glioma multicellular spheroids: diffusion and one-dimensional chemical shift nuclear magnetic resonance microscopy.
Schiffenbauer YS; Tempel C; Abramovitch R; Meir G; Neeman M
Cancer Res; 1995 Jan; 55(1):153-8. PubMed ID: 7805026
[TBL] [Abstract][Full Text] [Related]
51. A possible role of the creatine phosphate-creatine pool in the regulation of the adenylate pool.
Pezzini A; Conte A; Galbani P; Ronca-Testoni S
Int J Tissue React; 1988; 10(2):107-10. PubMed ID: 3182186
[TBL] [Abstract][Full Text] [Related]
52. Differential effects of creatine kinase isoenzymes and substrates on regeneration in livers of transgenic mice.
Askenasy N; Koretsky AP
Am J Physiol; 1997 Aug; 273(2 Pt 1):C741-6. PubMed ID: 9277372
[TBL] [Abstract][Full Text] [Related]
53. Cyclocreatine in cancer chemotherapy.
Teicher BA; Menon K; Northey D; Liu J; Kufe DW; Kaddurah-Daouk R
Cancer Chemother Pharmacol; 1995; 35(5):411-6. PubMed ID: 7850923
[TBL] [Abstract][Full Text] [Related]
54. Cyclocreatine transport and cytotoxicity in rat glioma and human ovarian carcinoma cells: 31P-NMR spectroscopy.
Schiffenbauer YS; Meir G; Cohn M; Neeman M
Am J Physiol; 1996 Jan; 270(1 Pt 1):C160-9. PubMed ID: 8772441
[TBL] [Abstract][Full Text] [Related]
55. Specific targeting of tumor cells by the creatine analog cyclocreatine.
Martin K; Winslow E; Okeefe M; Khandekar V; Hamlin A; Lillie J; Kaddurahdaouk R
Int J Oncol; 1996 Nov; 9(5):993-9. PubMed ID: 21541606
[TBL] [Abstract][Full Text] [Related]
56. A short review on creatine-creatine kinase system in relation to cancer and some experimental results on creatine as adjuvant in cancer therapy.
Patra S; Ghosh A; Roy SS; Bera S; Das M; Talukdar D; Ray S; Wallimann T; Ray M
Amino Acids; 2012 Jun; 42(6):2319-30. PubMed ID: 21769499
[TBL] [Abstract][Full Text] [Related]
57. [Kinetic patterns in the growth of transplantable mouse tumor RShM-1].
Svinogeeva TP; Konopliannikov AG; Shtein LV
Vopr Onkol; 1976; 22(9):62-6. PubMed ID: 1034368
[TBL] [Abstract][Full Text] [Related]
58. Cyclocreatine treatment improves cognition in mice with creatine transporter deficiency.
Kurosawa Y; Degrauw TJ; Lindquist DM; Blanco VM; Pyne-Geithman GJ; Daikoku T; Chambers JB; Benoit SC; Clark JF
J Clin Invest; 2012 Aug; 122(8):2837-46. PubMed ID: 22751104
[TBL] [Abstract][Full Text] [Related]
59. Antitumor activity of creatine analogs produced by alterations in pancreatic hormones and glucose metabolism.
Ara G; Gravelin LM; Kaddurah-Daouk R; Teicher BA
In Vivo; 1998; 12(2):223-31. PubMed ID: 9627806
[TBL] [Abstract][Full Text] [Related]
60. Protein kinase C--a novel target for rational anti-cancer drug design?
Gescher A; Dale IL
Anticancer Drug Des; 1989 Aug; 4(2):93-105. PubMed ID: 2679620
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
